



LSINW Information

Curevo Vaccine, Inc., privately held and founded in 2018. Headquartered in Bothell
Currently raising a Series B.
For more information, contact David Miller, Sr. Dir. Strategic Communications

About Curevo

Curevo Vaccine is a privately-held, clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent herpes zoster, commonly known as shingles. Our goal with a new herpes zoster vaccine is to improve the patient experience and, ultimately, overall vaccination rates, by developing amezosvatein as a vaccine with non-inferior efficacy combined with clinically-meaningful improvements in reactogenicity when compared to Shingrix.

On January 7, 2024, Curevo reported positive data from an 876-participant Phase 2 study head-to-head versus Shingrix testing different adjuvant and antigen dose levels. The Phase 2 data showed amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including a 100% vaccine response rate. Amezosvatein also met the primary safety endpoint, with lower local and systemic adverse events in this trial compared to Shingrix.